Boao, China — On the sidelines of the 2024 Boao Forum for Asia, AstraZeneca CEO Pascal Soriot shared his optimistic views on China’s economic growth and its burgeoning role as a global leader in innovation, particularly in the biopharmaceutical sector.
In an exclusive interview with CGTN’s Guan Xin, Soriot emphasized the importance of China’s efficient supply chain, highlighting its strategic significance to AstraZeneca’s global operations. “China’s supply chain has proven to be robust and reliable, enabling us to deliver life-saving medications efficiently worldwide,” he stated.
Soriot also lauded China’s commitment to innovation in biopharmaceuticals, noting that the country is rapidly becoming a hub for cutting-edge research and development. “The talent and resources available in China are unparalleled. We are excited to collaborate with local partners to advance healthcare solutions,” he added.
The AstraZeneca CEO’s comments come at a time when China continues to open up its markets and invest heavily in healthcare innovation, attracting international businesses and fostering global partnerships.
Reference(s):
cgtn.com
